Objective: To determine outcomes and risks of IV thrombolysis (IVT) in patients with acute ischemic stroke (AIS) .80 years of age within 3 hours compared to .3 to 4.5 hours recorded in the Safe Implementation of Treatment in Stroke (SITS) International Stroke Thrombolysis Registry.
Pooled analysis of randomized controlled trials (RCTs) of IV thrombolysis (IVT) for acute ischemic stroke has shown that patients .80 years of age treated with IVT vs controls derived equal benefit compared to patients 18 to 80 years of age. Within the .3-to 4.5-hour window, the effect was significant for younger patients (odds ratio [OR] 1.26, 95% confidence interval [CI] 1.04-1.54) but was not independently significant for the more elderly; however, the elderly sample was smaller and showed a greater point estimate (OR 1.36, 95% CI 0.87-2.14). 1 The effectiveness of IVT diminished as the treatment delay increased across the first 6 hours without a corresponding increase in the relative risk of symptomatic intracerebral hemorrhage (SICH).
Real-world registry experience supports these RCT data in patients .80 years of age treated within 3 hours. 2, 3 The Safe Implementation of Treatment in Stroke (SITS)-International Stroke Thrombolysis Register (ISTR)-Virtual International Stroke Trials Archive (VISTA) analysis demonstrated benefit of IVT in patients .80 years of age compared to controls and found no difference in the slope of benefit vs treatment delay for younger vs elderly patients, 3 a finding that was confirmed in the RCT dataset. 4 The European guideline 5 recommends use of IVT within 4.5 hours of symptom onset also in the elderly, but North American guidelines do not recommend IVT in the .3-to 4.5-hour window in patients .80 years old. 6 Most European regulatory agencies have not approved marketing of IVT with Actilyse for use in ischemic patients .80 years of age, whereas the American regulatory agency supports promotion of IVT in patients .80 years of age within 3 hours of symptom onset.
About 30% of admitted ischemic stroke patients are .80 years of age, 7, 8 but about twothirds of overall stroke-related morbidity and mortality occur in patients .80 years old. 9, 10 A large proportion of these elderly patients are possible candidates for thrombolysis. Divergent recommendations from professional bodies and regulatory agencies may have a negative impact on IVT treatment in elderly populations.
We used the SITS-ISTR to determine the outcomes and risks of IVT that are achieved in routine practice in patients .80 years of age in the .3-to 4.5-hour time window compared to within 3 hours.
METHODS Study design. This is an observational study based on retrospective analysis of a prospective registry.
Patient selection. Figure 1 shows the flow diagram for patient selection. In the primary analysis, we included unselected ischemic stroke patients .80 years of age who were treated with IV alteplase within 4.5 hours of symptom onset and registered in SITS-ISTR between 2003 and 2015. 11 Patients treated with mechanical thrombectomy or with unknown or missing stroke onset to treatment time (OTT) were excluded from the analysis. In the sensitivity analysis, we included only patients treated in compliance with the other European Summary of Product Characteristics (EU SmPC) criteria. European license restrictions of IV alteplase in acute ischemic stroke are described in the EU SmPC criteria. 12 In light of these, the following data were collected in the SITS-ISTR, and we excluded them from the sensitivity analysis: (1) severe stroke as assessed clinically (e.g., NIH Stroke Scale [NIHSS] score .25) or by appropriate imaging techniques; (2) administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory; (3) any history of stroke and concomitant diabetes mellitus; (4) stroke within the last 3 months; (5) systolic blood pressure .185 mm Hg, diastolic blood pressure .110 mm Hg, or aggressive management (IV medication) necessary to reduce blood pressure to these limits; (6) blood glucose ,50 or .400 mg/dL (,2.7 or .22.2 mmol/L), and (7) receiving oral anticoagulants, e.g., warfarin sodium.
We collected baseline and demographic characteristics, including stroke severity using the NIHSS and prestroke disability using the modified Rankin Scale (mRS); medication at stroke onset; risk factors; NIHSS score at 2 hours, 24 hours, and 7 days after treatment; brain imaging before IVT treatment; follow-up CT brain imaging at 24 to 36 hours and any other additional imaging scans to assess for hemorrhagic transformation (HT); and mRS score at 3 months.
Standard protocol approvals, registrations, and patient consents. The need for ethics approval or patient consent for participation in SITS-ISTR varied among participating countries, but approvals were obtained in countries that required it; other countries approved the register for conduct as an anonymized audit. The current study is a part of the SITS-Monitoring Study (MOST) II, which is approved by the Ethics Committee of the Karolinska Institute in Stockholm, Sweden.
The SITS International Coordination Office performed regular online monitoring of the SITS-ISTR data and checked individual patient data on a regular basis to handle errors or inconsistencies. For a sample of patients included in SITS-MOST (n 5 6,483), 8 source data were verified onsite by monitors under the supervision of their national coordinator.
Outcome measurements. The main outcome measurements were functional independence at 3 months, identified as an mRS score of #2; SICH per SITS-MOST, 13 defined as a local or remote parenchymal hemorrhage type 2 on the 22-to 36-hour posttreatment imaging scan or earlier if clinically indicated, combined with a neurologic worsening of $4 points in the NIHSS score between baseline and 24 hours or leading to death; and SICH per the European Cooperative Acute Stroke Study II (ECASS-2), 14 defined as any intracerebral hemorrhage on any posttreatment imaging scans combined with NIHSS score worsening $4 points between baseline and 7 days (ECASS definition). For comparison with other published work, we also analyzed the following outcomes: no/minimal disability, defined as an mRS score of 0 or 1 at 3 months; SICH per the National Institute of Neurological Disorders and Stroke (NINDS), 15 i.e., any intracerebral hemorrhage on any posttreatment imaging scans combined with any decline in neurologic status as measured by NIHSS between baseline and 7 days; death within 3 months; and HT categorized with the ECASS trial definitions. Statistical analysis. In the primary analysis, patients .80 years of age were divided into 2 groups according to stroke OTT: IVT initiated within 3 hours (the early cohort) and in .3 to 4.5 hours (the later cohort). Descriptive statistics for the baseline and demographic data were contrasted according to the early and the later cohort per OTT. Unknown or missing values were excluded from the denominator when proportions were calculated. HT, SICH, neurologic status until day 7 or discharge, and 90-days mortality and disability (mRS score) were compared between the 2 groups. We performed multivariable logistic regression analyses to examine whether the outcomes differ between the 2 OTT groups after adjustment for baseline imbalances. Unknown or missing values were excluded from the multivariable analysis. We performed sensitivity analysis for patients treated in compliance with the other EU SmPC criteria. The following variables were entered into the multivariable model as a predictor for outcome parameters on the basis of their statistical significance in the univariate analysis at the 10% level and known clinical importance to predict outcome even if p . 0.10: age, sex, baseline NIHSS, history of diabetes mellitus, hypertension, smoking, previous stroke within 3 months, atrial fibrillation, prestroke mRS, signs of current infarction, hyperdense artery sign, systolic blood pressure, and plasma glucose. Hospital arrival to treatment time was not included in the model because of collinearity with OTT. Values of p . 0.05 were regarded as statistically significant. All analyses were performed with STATISTICA software, version 13 (Palo Alto, CA).
RESULTS Between January 2003 and December 2015, 14,240 patients .80 years of age with acute ischemic stroke treated with IVT within 4.5 hours of symptom onset were recorded in the SITS-ISTR. These patients were recorded from 45 countries across 595 centers, and 94% (n 5 13,370) were from European countries. Patients treated within the 3-to 4.5-hour time window were registered from 38 countries across 399 clinical centers.
Baseline and demographic characteristics of patients .80 years of age treated with IVT within 3 to 4.5 hours are compared with those treated within 3 hours of symptom onset in table 1. In the later cohort, median time for IVT initiation was longer (83 minutes since stroke onset and 25 minutes since hospital arrival) and median stroke severity was lower (by 2 points as measured by NIHSS score) compared to the early cohort. Figure 2 and table e-1 at Neurology.org show the extent of hemorrhage found on any post-IVT imaging scans. The overall rate of HT was 19.1% vs 16. 1% (p 5 0.0001) in the later compared to the early time window. Patients who received IVT in the later cohort had slightly higher local type of hemorrhages compared to the early cohort (p 5 0.0001 for overall difference between groups). When tested within each hemorrhage type separately, hemorrhagic infarct type 1 (p 5 0.03) and primary intracerebral hemorrhage type 2 (p , 0.0001) appeared statistically significant between the groups. There was no difference regarding remote hemorrhages between the later and early cohorts (p 5 0.5). In patients treated within EU SmPC criteria, the overall rate of HT was 18.1% vs 15.7% (p 5 0.01), any primary intracerebral hemorrhage was 9.6% vs 8.1% (p 5 0.03), any local hemorrhages was 16.1% vs 13.6% (p 5 0.005), and remote hemorrhages was 3.5% vs 3.7% (p 5 0.52) in the later compared to the early time window, respectively.
Figure e-1 shows changes in NIHSS scores from baseline to 7 days. In both time windows, NIHSS score improved from baseline to 7 days.
In table 2, main outcome results are compared between the early and later cohorts. Patients .80 years of age treated in the later time window had a higher frequency of SICH in the univariate analysis and higher adjusted OR in the multivariable analysis compared to patients treated earlier. Patients .80 years of age treated in the later time window had a similar rate of functional outcome in the univariate analysis but had a lower OR for functional independence in the multivariable analysis compared to patients treated in the early time window. Mortality at 3 months did not differ statistically significantly between the early and later time windows in the univariate or multivariate analysis. Figure 3 shows the distribution of mRS scores at 3 months categorized by stroke OTT.
Patients compliant with the other EU SmPC criteria. In table e-2, baseline and demographic characteristics of patients .80 years of age treated with IVT in compliance with the other EU SmPC criteria are compared between the early and later cohorts. In the table 3, main outcome results are compared between the later and early cohorts for patients in compliance with the other EU SmPC criteria. Results were similar for the EU SmPC cohort and for the unselected cohort described above, but the overall outcomes in the EU SmPC cohort were better than in the unselected cohort in both time windows.
Patients with missing 3-month mRS score. In table e-3, baseline and demographic characteristics of patients missing 3-month outcome data are compared between the early and later time windows. There was no statistically significant difference between the early and later time window patients with regard to baseline characteristics except for higher frequency of previous stroke .3 months earlier (16% vs 12%, p 5 0.01), oral antihypertensive treatment (72% vs 68%, p 5 0.03), plasma glucose (6.8 vs 6.6 mmol/L, p 5 0.047), longer hospital arrival to treatment time (82 vs 59 minutes, p , 0.001), and lower NIHSS score (11 vs 13, p , 0.001) in the later compared to early time window, respectively. DISCUSSION This study with a large number of acute ischemic stroke patients .80 years old treated with IVT showed slightly higher frequency and adjusted OR (aOR) of SICH in the later (.3-4.5 hours) compared to earlier (#3 hours) time window. Table 1 Baseline The overall rate of HTs was also higher in the later compared to earlier time window. We did not detect a difference in SICH or overall HT rates between early and later cohorts in our first SITS publication on .3-to 4.5-hour time windows among patients up to 80 years of age. 16 The current study findings are consistent with a subsequent analysis of SITS in a larger cohort of EU SmPC-compliant patients up to 80 years of age that found higher rates of SICH per SITS in the .3-4.5-hour compared to 3-hour time window. 17 In a recent prospective study, SICH per ECASS-2 (aOR 1.46, p 5 0.05) and NINDS (aOR 1.35, p 5 0.07) was borderline significantly higher in the later time window compared to early time window. 18 In the pooled analysis of RCTs, there was no hint that HTs and SICH rates increase in the later treatment window (.3 hours) compared to earlier time window (#3 hours). The overall fatal intracranial hemorrhage rate was higher (3.6% vs 2.3%) in those .80 compared to #80 years of age. The smaller pooled analysis has not been published of patients .80 years of age and treated .3 hours. 1 We do not know if the higher HTs and SICH in the .3-to 4.5-hour time window observed in our study apply only for IVT-treated patients or are a natural phenomenon in control and IVT-treated patients because we lack a control group.
Postthrombolysis imaging scans were performed 81 minutes after stroke onset (25.6 hours in the 3-hour group vs 26.9 hours in the .3-to 4.5-hour group) in our study cohort, which may have contributed to slightly higher rates of visible HTs in the later than early cohort. A possible relation between onset Figure 2 Proportions of HT on postthrombolysis imaging scans in patients >80 years of age treated in early and later time windows EU SmPC 5 European Summary of Product Characteristics; HI 5 hemorrhagic infarct; HT 5 hemorrhagic transformation; OTT 5 onset to thrombolysis treatment time; PH 5 primary intracerebral hemorrhage; PHr 5 remote primary intracerebral hemorrhage. to assessment time and SICH rate that is independent of treatment was apparent in the control group of the pooled RCT published by the Stroke Thrombolysis Trialists' Collaboration. 4 The absolute incidence of SITS-MOST hemorrhage was 0.4% for ,3 hours, 0.6% for .3 to 4.5 hours, and 0.7% for .4.5 hours, although the small numbers do not permit reliable estimation and stratification by age groups was not performed.
In the unadjusted analysis, frequency of functional outcome (mRS score 0-2 and 0-1) and mortality at 3 months were similar between the .3-to 4.5-hour and #3-hour time windows. In the multivariable analyses, adjusted ORs were significantly lower for functional outcome (mRS score 0-2 and 0-1) at 3 months in the .3-to 4.5-hour compared to #3-hour group, but the OR for mortality did not differ significantly between the groups. The difference between unadjusted and adjusted analyses for functional outcome at 3 months could be partly explained by less severe stroke in the .3-to 4.5-hour group (2-point-lower median NIHSS score) compared to the 3-hour group. However, patients treated in the .3-to 4.5-hour time window had a higher prevalence of some characteristics associated with worse outcome, specifically higher prestroke functional dependency, diabetes mellitus, previous smoking, antihypertensive treatment, signs of current infarction in the imaging scans, and plasma glucose. Longer stroke OTT is one of the powerful predictors of poor outcome after thrombolysis yet defines the distinction between the 3-to 4.5-hours and #3-hour cohorts. Prestroke disability may have been underestimated. The reliability of premorbid mRS assessment may be questioned when undertaken rapidly in elderly patients who are less likely to have reliable witnesses on hand and when treatment options may be known to be influenced by admission of disability; delay in reaching hospital after acute stroke may be associated with such premorbid disability. These and other unidentified imbalances may have contributed poor outcome despite our efforts to achieve appropriate statistical adjustment for imbalances in the multivariable analyses.
In the sensitivity analysis for patients treated according to the other EU SmPC criteria, the results are similar compared to unselected population. The current study results in EU SmPC patients are in line with previous SITS publications in which we compared outcomes between the early and later time windows in patients #80 years of age who were compliant with the EU SmPC criteria. [16] [17] [18] [19] In those studies, the outcomes were poorer among patients treated in the later time window. It is also important to note that the statistical significance will be driven heavily by the large sample size. Although SICH rate was higher in the later than early time window, the absolute difference between the groups was small (ranging between 1.1% and 1.8%, depending on the definition of SICH); these differences may not be clinically significant because elderly patients generally have poor outcome if untreated.
Our study has several limitations. Important limitations are the observational design and lack of a control group without IVT treatment. There are some baseline imbalances between the groups that may have biased the study results. The statistically significant baseline differences between the groups are probably not clinically relevant because they differ in the range of 1% to 3% and became statistically significant as a result of the large sample size. Baseline stroke severity was 2 points lower and hospital arrival to treatment time was 25 minutes longer in the later Figure 3 Distribution of mRS scores at 3 months in all patients >80 years and in patients >80 years old treated according to other EU SmPC criteria categorized by stroke OTT EU SmPC 5 European Summary of Product Characteristics; mRS 5 modified Rankin Scale; OTT 5 onset to treatment time.
group than the early group. Although we performed multivariable analysis to adjust for recorded baseline differences, this may not account for all imbalances or may overemphasize the observed imbalances. A final limitation is the extent of missing data, in particular 3-month outcome data, which were missing for z25% of patients. We analyzed baseline and demographic characteristics of these patients with missing data. We did not detect any major imbalance in the nature or extent of messiness between the later and earlier time windows, and the affected patients appear similar to patients with known outcomes. Nevertheless, this is a major source of potential bias that warrants extremely cautious interpretation of the findings. Ischemic stroke patients .80 years of age treated with IVT in the later time window had slightly higher SICH and had similar unadjusted functional outcome but poorer outcome when adjusted for baseline imbalances in unselected patients compared to patients treated within 3 hours. The absolute difference between the treatment groups is small, and elderly patients should not be denied IVT in the later time window solely because of age without other contraindications. Caution is required to interpret these results that come from an observational, uncontrolled registry; similar findings were previously reported for patients #80 years of age.
AUTHOR CONTRIBUTIONS
N. Ahmed designed the study and write the first draft of the manuscript in close collaboration with G.A. Ford, K.R. Lees, and D. Toni. P.A. Ringleb, C. Bladin, and D. Collas were coordinators for the top recruiting center and contributed to the manuscript by their comments. N. Ahmed had full access to all the data in the study, conducted and is responsible for the statistical analysis, and takes responsibility for the integrity of the data and the accuracy of the data analysis. Table 3 Proportion and aOR of main outcomes in patients >80 years old treated in the early time window compared to patients treated in the later time window otherwise compliant with the EU SmPC criteria 
